Neurogen Corporation Earnings Conference Call (Q4 2007)  Today's Calls

Visit the TF Network Sites· Corporate IR Center · Institutional Investor Center · Individual Investor Center Download Plug-In Real Player 8 Basic Windows Media Player Other Conference Calls Other Mar 17 Calls Today's Calls

Call Details Neurogen Corporation Earnings Conference Call (Q4 2007) Mon, Mar 17, 2008, 8:30 am Eastern Listen to the archived event audio About Neurogen Corporation (NasdaqGM:NRGN) Other Calls  Neurogen Corporation, a drug discovery and development company, focuses on new small molecule drugs for various disorders, including insomnia, pain, Parkinson’s disease, restless legs syndrome, anxiety, and schizophrenia. Its clinical development programs include adipiplon, which is in Phase II/III clinical trials for the treatment of insomnia, and completed Phase I clinical trials for the treatment of anxiety and schizophrenia; NGD-8243/MK 2295, a Phase I clinical trial compound for the treatment of pain and cough; and aplindore, which is in Phase II clinical trials for the treatment of Parkinson’s disease and restless legs syndrome. Neurogen has collaborations with Wyeth Pharmaceuticals to acquired worldwide rights to aplindore; and Merck & Co., Inc. to research, develop, and commercialize small molecule medicines that work by targeting VR1. The company was founded in 1987 and is based in Branford, Connecticut. More Info: Quote | Chart | News | Profile | Reports | Research | SEC | Msgs | Insider | Financials | Analyst Ratings